<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04535544</url>
  </required_header>
  <id_info>
    <org_study_id>CR108868</org_study_id>
    <secondary_id>2020-001249-37</secondary_id>
    <secondary_id>73763989HPB2004</secondary_id>
    <nct_id>NCT04535544</nct_id>
  </id_info>
  <brief_title>A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus</brief_title>
  <acronym>REEF-D</acronym>
  <official_title>A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled Study With Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate on-treatment efficacy against hepatitis D virus (HDV)&#xD;
      of JNJ-73763989 + nucleos(t)ide analog (NA) regimen compared to NA alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      JNJ-73763989 is a liver-targeted antiviral therapeutic for subcutaneous injection designed to&#xD;
      treat chronic hepatitis B virus (HBV) infection via ribonucleic acid interference mechanism.&#xD;
      This phase 2 study is designed to evaluate safety and efficacy of JNJ-73763989 in HBV&#xD;
      infected patients who are co-infected with HDV. The study consists of 2 parts: Part 1 will&#xD;
      evaluate safety, tolerability and antiviral activity of JNJ-73763989 + NA while Part 2 will&#xD;
      evaluate the safety and efficacy of the JNJ-73763989 + NA regimen in the treatment of HBV/HDV&#xD;
      co-infection. Each part includes 3 phases: Screening phase (from 4 Week up to maximum of 8&#xD;
      weeks), Intervention phase (144 Week for Arm A and 148 Week for Arm B) and Follow-up phase&#xD;
      (48 Week). The duration of individual study participation will be between 196 and 204 weeks.&#xD;
      Safety and tolerability (including adverse events [AEs] and Serious AEs, laboratory&#xD;
      assessments, electrocardiogram [ECG], vital signs, physical examination), efficacy (including&#xD;
      HDV ribonucleic acid [RNA], HBV deoxyribonucleic acid [DNA] and antigens) , and&#xD;
      pharmacokinetics will be assessed throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 7, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with HDV RNA &gt;=2 log10 IU/mL Decline From Baseline or HDV RNA TND in Combination with Normal ALT at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Percentage of participants with hepatitis D virus (HDV) ribonucleic acid (RNA) greater than or equal to (&gt;=) 2 log10 international units per milliliter (IU/mL) decline from baseline or HDV RNA target not detected (TND) in combination with normal alanine aminotransferase (ALT) at Week 48 will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HDV RNA &gt;=2 log10 IU/mL Decline From Baseline or HDV RNA TND at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Percentage of participants with HDV RNA &gt;=2 log10 IU/mL decline from baseline or HDV RNA TND at Week 48 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Normal ALT at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Percentage of participants with normal ALT at Week 48 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with &gt;=2 kPa Reduction From Baseline in LSM assessed by VCTE (FibroScan) at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Percentage of participants with &gt;=2 kilopascal (kPa) reduction from baseline in liver stiffness measurement (LSM) assessed by vibration-controlled transient elastography (VCTE) (FibroScan) at Week 48 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBsAg Seroclearance at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Percentage of participants with hepatitis B s antigen (HBsAg) seroclearance at Week 48 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HDV RNA &gt;=2 log10 IU/mL Decline From Baseline or HDV RNA TND in Combination with Normal ALT</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Percentage of participants with HDV RNA &gt;=2 log10 IU/mL decline from baseline or HDV RNA TND in combination with normal ALT will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HDV RNA &gt;=2 log10 IU/mL Decline From Baseline in Combination with Normal ALT</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Percentage of participants with HDV RNA &gt;=2 log10 IU/mL decline from baseline in combination with normal ALT will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HDV RNA TND in Combination with Normal ALT</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Percentage of participants with HDV RNA TND in combination with normal ALT will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HDV RNA &gt;=2 log10 IU/mL Decline From Baseline or HDV RNA TND</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Percentage of participants with HDV RNA &gt;=2 log10 IU/mL decline from baseline or HDV RNA TND will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HDV RNA &gt;=2 log10 IU/mL Decline From Baseline</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Percentage of participants with HDV RNA &gt;=2 log10 IU/mL decline from baseline will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HDV RNA TND</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Percentage of participants with HDV RNA TND will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Normal ALT</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Percentage of participants with normal ALT will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach HDV RNA &gt;=2 log10 IU/mL Decline or HDV RNA TND</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Time to reach HDV RNA &gt;=2 log10 IU/mL decline or HDV RNA TND will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in HDV RNA</measure>
    <time_frame>Baseline and up to Week 204</time_frame>
    <description>Change from baseline in HDV RNA will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in ALT</measure>
    <time_frame>Baseline and up to Week 204</time_frame>
    <description>Changes from baseline in ALT will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs) and Serious AEs</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormalities in Laboratory Parameters</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Percentage of participants with abnormalities in laboratory parameters (hematology, blood biochemistry, blood coagulation, urinalysis, urine chemistry, and renal biomarkers) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormalities in 12-lead Electrocardiogram (ECGs)</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Percentage of participants with abnormalities in 12-lead electrocardiogram (ECGs) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormalities in Vital Signs</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Percentage of participants with abnormalities in vital signs (systolic and diastolic blood pressure, pulse rate, and body temperature) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormalities in Physical Examination</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Percentage of participants with abnormalities in physical examination will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBsAg Seroclearance and/or Seroconversion</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Percentage of participants with HBsAg seroclearance and/or seroconversion will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Over Time in HBsAg</measure>
    <time_frame>Baseline and up to Week 204</time_frame>
    <description>Change from baseline over time in HBsAg will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Over Time in HBeAg</measure>
    <time_frame>Baseline and up to Week 204</time_frame>
    <description>Change from baseline over time in HBeAg will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Over Time in HBV DNA</measure>
    <time_frame>Baseline and up to Week 204</time_frame>
    <description>Change from baseline over time in HBV DNA will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBsAg levels below/above different cut-offs</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Percentage of participants with HBsAg levels below/above different cut-offs will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBeAg levels below/above different cut-offs</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Percentage of participants with HBeAg levels below/above different cut-offs will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBV DNA levels below/above different cut-offs</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Percentage of participants with HBV DNA levels below/above different cut-offs will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBsAg Change From Baseline Below/Above Different Cut-offs</measure>
    <time_frame>Baseline and up to Week 204</time_frame>
    <description>Percentage of participants with HBsAg change from baseline below/above different cut-offs will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBeAg Change From Baseline Below/Above Different Cut-offs</measure>
    <time_frame>Baseline and up to Week 204</time_frame>
    <description>Percentage of participants with HBeAg change from baseline below/above different cut-offs will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBV DNA Change From Baseline Below/Above Different Cut-offs</measure>
    <time_frame>Baseline and up to Week 204</time_frame>
    <description>Percentage of participants with HBV DNA change from baseline below/above different cut-offs will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Efficacy Thresholds such as HBsAg &lt;1 IU/mL</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Time to reach efficacy thresholds such as HBsAg &lt;1 IU/mL will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBV DNA Virologic Breakthrough</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Percentage of participants with virologic breakthrough (defined as confirmed on-treatment HBV DNA increase by greater than [&gt;] 1 log10 IU/mL from nadir level or confirmed on treatment level &gt;200 IU/mL in participants who had HBV DNA level below &lt; lower limit of quantification [LLOQ] of the HBV DNA assay) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve (AUC) of JNJ-73763989 and Optionally NA</measure>
    <time_frame>Up to Week 124</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) of JNJ-73763989 and optionally NA will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with &gt;=2 kPa Reduction from Baseline in LSM Assessed by VCTE (FibroScan)</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Percentage of participants with &gt;=2 kPa reduction from baseline in LSM assessed by VCTE (FibroScan) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in LSM Over Time Assessed by VCTE (FibroScan)</measure>
    <time_frame>Baseline and up to Week 204</time_frame>
    <description>Change from baseline in LSM over time assessed by VCTE (FibroScan) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Sustained HDV Response Off-treatment Post end of JNJ-73763989 Treatment</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Percentage of participants with sustained HDV response off-treatment post end of JNJ-73763989 treatment will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HDV Relapse Post End of JNJ 73763989 Treatment</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Percentage of participants with HDV relapse post end of JNJ 73763989 treatment will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Sustained HBV Response Off-Treatment Post End of JNJ-73763989 Treatment.</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Percentage of participants with sustained HBV response off-treatment post end of JNJ-73763989 treatment will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBV Flare (Virologic, Biochemical, and Clinical) Post End of Treatment</measure>
    <time_frame>Up to Week 204</time_frame>
    <description>Percentage of participants with HBV flare (virologic, biochemical, and clinical) post end of treatment will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hepatitis B Quality of Life (HBQOL) Scale And Subscales</measure>
    <time_frame>Baseline and up to Week 204</time_frame>
    <description>HBQOL is a 31-item disease-specific instrument designed to measure HRQOL for participants with chronic hepatitis B (CHB). Score ranges from 0 to 100, where lower scores denote less Health-related Quality of Life (HRQOL) impact, and higher scores denote more HRQOL impact (that is 0=best score and 100=worst score).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Hepatitis D, Chronic</condition>
  <arm_group>
    <arm_group_label>Immediate Active Treatment arm: JNJ-73763989 + NA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-73763989 subcutaneous (SC) injection every 4 weeks (Q4W) along with NA (entecavir [ETV], tenofovir disoproxil, or tenofovir alafenamide [TAF]) once daily for 144 Weeks in Part 1 and 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferred Active Treatment arm: Placebo+NA+JNJ-73763989+NA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo to JNJ-73763989 SC injection Q4W along with NA (ETV, tenofovir disoproxil, or TAF) once daily for 52 Weeks followed by JNJ-73763989 SC injection Q4W along with NA once daily for 96 weeks in Part 1 and 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-73763989</intervention_name>
    <description>JNJ-73763989 will be administered as a SC injection.</description>
    <arm_group_label>Deferred Active Treatment arm: Placebo+NA+JNJ-73763989+NA</arm_group_label>
    <arm_group_label>Immediate Active Treatment arm: JNJ-73763989 + NA</arm_group_label>
    <other_name>JNJ-3989</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to JNJ-73763989 will be administered as a SC injection.</description>
    <arm_group_label>Deferred Active Treatment arm: Placebo+NA+JNJ-73763989+NA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir (ETV) monohydrate</intervention_name>
    <description>ETV monohydrate film coated tablet will be administered orally.</description>
    <arm_group_label>Deferred Active Treatment arm: Placebo+NA+JNJ-73763989+NA</arm_group_label>
    <arm_group_label>Immediate Active Treatment arm: JNJ-73763989 + NA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil</intervention_name>
    <description>Tenofovir disoproxil film-coated tablet will be administered orally.</description>
    <arm_group_label>Deferred Active Treatment arm: Placebo+NA+JNJ-73763989+NA</arm_group_label>
    <arm_group_label>Immediate Active Treatment arm: JNJ-73763989 + NA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir alafenamide (TAF)</intervention_name>
    <description>TAF film coated tablet will be administered orally.</description>
    <arm_group_label>Deferred Active Treatment arm: Placebo+NA+JNJ-73763989+NA</arm_group_label>
    <arm_group_label>Immediate Active Treatment arm: JNJ-73763989 + NA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Medically stable based on physical examination, medical history, vital signs,&#xD;
             electrocardiogram (ECG) at screening&#xD;
&#xD;
          -  Chronic hepatitis B virus (HBV) and hepatitis D virus (HDV) co-infection with&#xD;
             documentation at least 6 months prior to screening&#xD;
&#xD;
          -  Hepatitis D RNA (HDV RNA) greater than (&gt;) 1000 international units per milliliter&#xD;
             (IU/mL) at screening&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) greater than upper limit normal (ULN) but less than 10&#xD;
             times (ULN)&#xD;
&#xD;
          -  Body mass index (BMI) between 18.0 and 35.0 kilogram per meter square (kg/m^2),&#xD;
             extremes included&#xD;
&#xD;
          -  Highly effective contraceptive measures in place for female participants of&#xD;
             childbearing potential or male participants with female partners of childbearing&#xD;
             potential&#xD;
&#xD;
          -  Non-cirrhotic participants and participants with compensated cirrhosis (Child Pugh&#xD;
             class A) at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of infection with hepatitis A, C, or E virus infection or evidence of human&#xD;
             immunodeficiency, virus type 1 (HIV-1) or HIV-2 infection at screening&#xD;
&#xD;
          -  History or evidence of clinical signs/symptoms of hepatic decompensation including but&#xD;
             not limited to: portal hypertension, ascites, hepatic encephalopathy, esophageal&#xD;
             varices or any laboratory abnormalities indicating a reduced liver function as defined&#xD;
             in the protocol&#xD;
&#xD;
          -  Evidence of liver disease of non-HBV/HDV etiology&#xD;
&#xD;
          -  Signs of hepatocellular carcinoma (HCC)&#xD;
&#xD;
          -  Significant laboratory abnormalities as defined in the protocol at screening&#xD;
&#xD;
          -  Participants with a history of malignancy within 5 years before screening&#xD;
&#xD;
          -  Abnormal sinus rhythm or ECG parameters at screening as defined in the protocol&#xD;
&#xD;
          -  History of or current cardiac arrhythmia or history or clinical evidence of&#xD;
             significant or unstable cardiac disease&#xD;
&#xD;
          -  Participants with any current or previous illness for which, in the opinion of the&#xD;
             investigator and/or sponsor, participation would not be in the best interest of the&#xD;
             participant&#xD;
&#xD;
          -  History of or current clinically significant skin disease or drug rash&#xD;
&#xD;
          -  Participants with known allergies, hypersensitivity, or intolerance to JNJ-3989 or its&#xD;
             excipients or excipients of the placebo content&#xD;
&#xD;
          -  Contraindications to the use of entecavir (ETV), tenofovir disoproxil fumarate (TDF),&#xD;
             or tenofovir alafenamide (TAF) per local prescribing information&#xD;
&#xD;
          -  Participants who have taken any therapies disallowed per protocol&#xD;
&#xD;
          -  Female participants who are pregnant, or breast-feeding, or planning to become&#xD;
             pregnant while enrolled in this study or within 90 days after the last dose of study&#xD;
             intervention&#xD;
&#xD;
          -  Male participants who plan to father a child while enrolled&#xD;
&#xD;
          -  Participants who had or planned major surgery, (example, requiring general anesthesia)&#xD;
             or who have received an organ transplant&#xD;
&#xD;
          -  Vulnerable participants (example, incarcerated individuals, individuals under a legal&#xD;
             protection measure)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruane Clinical Research Group Inc</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southern California GI and Liver Center</name>
      <address>
        <city>San Clemente</city>
        <state>California</state>
        <zip>92673</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Harvard Medical School - Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>I.D. Care, Inc.</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Eastern Health Research</name>
      <address>
        <city>Box Hill</city>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico De Roraima</name>
      <address>
        <city>Boa Vista</city>
        <zip>69304015</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundação De Medicina Tropical Doutor Heitor Vieira Dourado</name>
      <address>
        <city>Manaus</city>
        <zip>69040-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cepem - Centro de Pesquisa Em Medicina Tropical</name>
      <address>
        <city>Porto Velho</city>
        <zip>76812-329</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Ditan Hospital Capical Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100015</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Bethune Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <zip>400010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guangzhou Eighth People's Hospital, Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University College of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes hôtel-Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10439</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Johann Wolfgang Goethe- Universität Frankfurt Medizinische Klinik 1</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Irccs Ospedale Maggiore Di Milano</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Roma 'La Sapienza' - Umberto I Policlinico di Roma</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Molinette, AO Città della Salute e della Scienza di</name>
      <address>
        <city>Tourin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical and Dental University Medical Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Nagasaki Medical Center</name>
      <address>
        <city>Nagasaki</city>
        <zip>856-8562</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of the Ryukyus Hospital</name>
      <address>
        <city>Nakagami gun</city>
        <zip>903-0215</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita-shi</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Zealand Clinical Research</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Irkutsk State Medical University</name>
      <address>
        <city>Irkutsk</city>
        <zip>664003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Republic Clinical Infectious Hospital n.a. AF Agafonov</name>
      <address>
        <city>Kazan</city>
        <zip>420140</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk Regional Center For AIDS And Infectious Diseases Treatment And Prophylaxis</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Petersburg City Center for AIDS and Infectious Diseases Treatment and Prophylaxis</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Company Hepatolog Ltd</name>
      <address>
        <city>Samara</city>
        <zip>443045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Smolensk Regional Clinical Hospital</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>North East Federal University n.a. M.K.Amosov</name>
      <address>
        <city>Yakutsk</city>
        <zip>677000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Vall D Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Danderyds Sjukhus</name>
      <address>
        <city>Danderyd</city>
        <zip>18288</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skanes universitetssjukhus</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Tiachung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>6230</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istanbul University Cerrahpasa Medical Faculty</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ege University Medical of Faculty, Department of Gastroenterology</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kocaeli University Medical Faculty</name>
      <address>
        <city>Kocaeli</city>
        <zip>41001</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Acibadem Mehmet Ali Aydinlar University</name>
      <address>
        <city>Kucukcekmece</city>
        <zip>34303</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karadeniz Teknik University Medical Faculty</name>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Free London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW32QR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St George's, University of London and St George's University Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>New Zealand</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108868</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 28, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2020</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis D</mesh_term>
    <mesh_term>Hepatitis D, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency.&#xD;
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

